We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov

Key Record Dates

ClinicalTrials.gov Identifier: NCT03945773
Brief Title: Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors (CaboPoint)

First Submitted : May 9, 2019
First Submitted that Met QC Criteria : May 9, 2019
First Posted : May 10, 2019

Last Update Submitted that Met QC Criteria : July 19, 2022
Last Update Posted : July 20, 2022